

ESPS JOURNAL EDITOR-IN-CHIEF'S REVIEW REPORT

Name of journal: World Journal of Ophthalmology

ESPS manuscript NO: 17182

Title: Curing diabetic retinopathy: Is a strategy emerging?

Journal Editor-in-Chief (Associate Editor): Umit Ubeyt Inan

Country: Turkey

Editorial Director: Xiu-Xia Song

Date sent for review: 2015-08-07 17:47

Date reviewed: 2015-08-11 07:22

ACADEMIC CONTENT EVALUATION	LANGUAGE QUALITY EVALUATION	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Revision
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		

JOURNAL EDITOR-IN-CHIEF (ASSOCIATE EDITOR) COMMENTS TO AUTHORS

Dear Author Your work is about on topical subject. Diabetic retinopathy is still a great pathology leading to severe vision loss in many eyes. Anti-VEGF treatment if given persistently for about 24 months leads to reversal of findings of diabetic retinopathy with a cleared retinal picture. A significant problem to achieve this fantastic and dream-like result is to afford the monthly injections. Sustained release drug platforms to deliver anti-VEGF substance for a long-time may be a good solution to overcome current obstacles. Your work summaries and encapsulate this subject very well. Our reviewers strongly suggested publication of your editorial writing. It is great pleasure to inform you that your enthusiastic writing is accepted for publication in the journal of WJO. Thank you very much for your support to the WJO.